Back to top
more

Coherus BioSciences (CHRS)

(Delayed Data from NSDQ)

$2.22 USD

2.22
1,302,038

-0.05 (-2.20%)

Updated May 6, 2024 04:00 PM ET

After-Market: $2.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Jun 7, 2021

Companies in the news are: REGN, CHRS, SENS, CGEM

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CHRS or ILMN: Which Is the Better Value Stock Right Now?

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

What's in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again

Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CHRS or ILMN: Which Is the Better Value Stock Right Now?

CHRS vs. ILMN: Which Stock Is the Better Value Option?

Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anirudha Bhagat headshot

Check These 7 Top-Ranked Stocks With Solid Net Profit Margins

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products

Tirthankar Chakraborty headshot

Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners

Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.

Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?

Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.